VA/DoD Clinical Practice Guidelines
FDA Warning
UPDATE-March 28, 2012
CITALOPRAM HYDROBROMIDE (CELEXA®)AND DOSE-DEPENDENT QT INTERVAL PROLONGATION
Post-marketing reports of QT interval prolongation and Torsades de Pointes associated with CELEXA® and its generic equivalents (citalopram) resulted in changes to the product labeling in August 2011. The Food and Drug Administration (FDA) announced further labeling changes on March 28,2012. Link to Citalopram Notice
UPDATE - September 15, 2015
CLOZAPINE: Drug Safety Communication - FDA Modifies Monitoring for Neutropenia; Approves New Shared REMS Program
FDA is making changes to the requirements for monitoring, prescribing, dispensing, and receiving the schizophrenia medicine clozapine, to address continuing safety concerns and current knowledge about a serious blood condition called severe neutropenia. Severe neutropenia is a dangerously low number of neutrophils, white blood cells that help fight infections. Severe neutropenia can be life-threatening. Link to Clozapine Notice